Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00020683 · ClinicalTrials.gov registry record · Phase 2
A Phase II Trial of COL-3 in Patients With HIV Related Kaposi's Sarcoma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT00020683: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00020683 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 70 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00020683, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
COL-3 may stop the growth of cancer by stopping blood flow to the tumor. Randomized phase II trial to compare the effectiveness of two different regimens of COL-3 in treating patients who have HIV-related Kaposi's sarcoma.
Interventions
- OTHER laboratory biomarker analysis
- DRUG incyclinide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2003-03 |
| Est. Completion | 2009-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00020683
The ClinicalTrials.gov registry entry for NCT00020683 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00020683 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00020683 about?
NCT00020683 is a clinical study titled "A Phase II Trial of COL-3 in Patients With HIV Related Kaposi's Sarcoma". COL-3 may stop the growth of cancer by stopping blood flow to the tumor. Randomized phase II trial to compare the effectiveness of two different regimens of COL-3 in treating patients who have HIV-related Kaposi's sarcoma.
What is the current status of trial NCT00020683?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2003-03. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00020683?
The interventions under investigation include: laboratory biomarker analysis (OTHER), incyclinide (DRUG).
Who is sponsoring clinical trial NCT00020683?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.